The single source of truth for proprietary protein structure data
A high-performance enterprise system for the storage, retrieval, and analysis of protein structures.
The foundation for structure-based discovery
Proasis is designed to bridge this gap by providing a single, high-performance platform which curates your in-house experimental protein structure data, augments this with the public domain dataset, and links with proprietary cutting-edge analysis tools, all packaged together in one enterprise system. It is more than a database; it is a knowledge hub for your entire research organisation that serves as the foundation for all discovery projects.
Why Proasis is the enterprise standard
Centralised intelligence
Designed to handle the scale of global pharmaceutical research, Proasis centralises fragmented experimental data into a secure and searchable environment.
Seamless workflow integration
It features an extensive API and CLI that allows for seamless integration with internal data pipelines and third-party modelling software.
Scalable infrastructure
Whether you are a specialist lab focused on fragment-based drug discovery or a global enterprise managing a massive data mesh, the system scales with your ambition.
Advanced data integrity
We prioritise data accuracy above all else, ensuring that new AI models are trained and tested on up-to-date, high-quality structure data.
Specialised support for biologics and antibodies
Proasis provides a sophisticated environment for navigating the complexities of biologics discovery.
Core functionality for computational teams
Are you ready to centralise your structural data? Get in touch to request a Proasis demo.
API and CLI power
Proasis Pro exposes 90% more advanced functionality, allowing computational teams to build custom workflow automations.
Unified enterprise system
Proasis serves as the high-performance platform providing the secure data pipeline through our integrated analysis tools, delivering the essential 3D structure biology context required for Raptor, Scorpion, Viper AI and our forthcoming Scorpius engine.
Frequently asked questions
Common questions related to our products, integration, and services.
What is Proasis and what does it do?
Proasis is DesertSci's enterprise protein structure database and visualisation platform, purpose-built for structure-based drug discovery (SBDD). It gives research teams a single, centralised source of truth for protein-ligand and protein-protein structure data, for both inhouse and public domain data, combining storage, retrieval, visualisation and annotation in one system, backed by 25 years of development specifically for medicinal chemistry and structural biology workflows.
Who is it designed for?
Proasis is designed for the multidisciplinary teams behind structure-based drug discovery, structural biologists and crystallographers, molecular modellers, medicinal chemists, bioinformatics teams, and computational chemists, as well as the IT and data teams who need an enterprise-grade platform to support them.
What problems does it solve?
Proasis replaces fragmented, siloed storage of structural data (spreadsheets, shared drives, individual crystallography software) with a single managed database system. It facilitates publication and data distribution for structural biology, automates routine tasks for molecular modellers, delivers structural information in an easy-to-use format for chemists, and lets teams cross-reference in-house structures against public domain data (PDB), accelerating candidate identification and reducing the time scientists spend hunting for or re-processing data.
What makes it different from competitors?
Proasis is designed for the multidisciplinary teams behind structure-based drug discovery, structural biologists and crystallographers, molecular modellers, medicinal chemists, bioinformatics teams, and computational chemists, as well as the IT and data teams who need an enterprise-grade platform to support them.
What plans & features are available?
Proasis is available across a small number of product tiers with different feature sets and pricing, plus a standalone AI-based drug design offering (Viper). Please see our website for information.
Does Proasis integrate with other tools?
Yes, and this is one of Proasis's strongest differentiators. The platform exposes an extensive, fully documented REST API covering search, download, data upload, and record modification, so structural data isn't locked inside a UI, it can be pulled directly into internal pipelines, AI/ML workflows, electronic lab notebooks, and computational chemistry tools. Combined with automated data deposition (dropbox-style folder monitoring) and broad format support (PDB, mmCIF, and server-side conversion tools), Proasis is built to sit inside a client's wider data ecosystem rather than as a standalone silo, a level of programmatic access many competitor platforms don't offer.
Is deposition automated?
Yes. Proasis supports automated deposit via dropbox-style directory monitoring, so new structures can be picked up automatically from a watched folder. This extends to shared volumes and common cloud storage locations.
Are there API resources available?
Yes, Proasis exposes an extensive REST API supporting searching, downloading, uploading data, and modifying records, with authentication. Developer documentation is available on request.
Is there a permission system to limit user access to specific structures?
Yes. Access is managed through role-based access controls, with the ability to blacklist and/or whitelist or restrict access to specific data subsets and configure flexible project hierarchies, so organisations can control exactly which teams or users see which structures or projects.
What other modalities does Proasis support?
Beyond standard small-molecule protein complexes, Proasis supports peptide complexes, nucleotides (DNA/RNA), antibody-drug conjugates (ADCs), and a broad range of standard and non-standard biologics assemblies, including AFFIMER, DARPIN, FAB, FC, full-length antibodies, FV, IgG, IgM, IgE, nanobodies (NB), scFv, and T-cell receptors (TR), as well as cryo-EM structures and AI-predicted models such as AlphaFold.
